TY - JOUR
T1 - Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis
AU - Richards, Danielle
AU - Morren, John A.
AU - Pioro, Erik P.
N1 - Funding Information:
The authors have no funding acknowledgements or conflicts to declare pertaining to this report. EPP has received clinical trial and research funding from ALS Association, Biogen, Inc. Biohaven Pharmaceuticals, and NIH/CDC. He has received consulting fees from Avanir Pharmaceuticals, Inc. Biohaven Pharmaceuticals, Inc. Cytokinetics, Inc. ITF Pharma, Inc. MT Pharma America, Inc. Neurotherapia, Inc. and Otsuka America, Inc.
Funding Information:
The authors have no funding acknowledgements or conflicts to declare pertaining to this report. EPP has received clinical trial and research funding from ALS Association, Biogen, Inc., Biohaven Pharmaceuticals, and NIH/CDC. He has received consulting fees from Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Inc., Cytokinetics, Inc., ITF Pharma, Inc., MT Pharma America, Inc., Neurotherapia, Inc., and Otsuka America, Inc.
Publisher Copyright:
© 2020 The Authors
PY - 2020/10/15
Y1 - 2020/10/15
N2 - Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative neuromuscular disease with limited treatment options. The diagnosis of ALS can be challenging for numerous reasons, resulting in delays that may compromise optimal management and enrollment into clinical trials. Several studies have examined the process and challenges regarding the clinical diagnosis of ALS. Twenty-one studies that were almost exclusively from the English literature published between 1990 and 2020 were identified via PubMed using relevant search terms and included patient populations from the United States, Canada, Japan, Egypt, and several countries in South America and Europe. Probable or definitive ALS patients were identified using El Escorial or revised El Escorial/Airlie House Criteria. Time to diagnosis or diagnostic delay was defined as mean or median time from patient-reported first symptom onset to formal diagnosis by a physician, as recorded in medical records. The typical time to diagnosis was 10–16 months from symptom onset. Several points of delay in the diagnosis course were identified, including specialist referrals and misdiagnoses, often resulting in unnecessary procedures and surgeries. Bulbar onset was noted to significantly reduce time to ALS diagnosis. Future interventions and potential research opportunities were reviewed.
AB - Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative neuromuscular disease with limited treatment options. The diagnosis of ALS can be challenging for numerous reasons, resulting in delays that may compromise optimal management and enrollment into clinical trials. Several studies have examined the process and challenges regarding the clinical diagnosis of ALS. Twenty-one studies that were almost exclusively from the English literature published between 1990 and 2020 were identified via PubMed using relevant search terms and included patient populations from the United States, Canada, Japan, Egypt, and several countries in South America and Europe. Probable or definitive ALS patients were identified using El Escorial or revised El Escorial/Airlie House Criteria. Time to diagnosis or diagnostic delay was defined as mean or median time from patient-reported first symptom onset to formal diagnosis by a physician, as recorded in medical records. The typical time to diagnosis was 10–16 months from symptom onset. Several points of delay in the diagnosis course were identified, including specialist referrals and misdiagnoses, often resulting in unnecessary procedures and surgeries. Bulbar onset was noted to significantly reduce time to ALS diagnosis. Future interventions and potential research opportunities were reviewed.
KW - Amyotrophic lateral sclerosis
KW - Diagnostic delay
KW - Motor neuron disease
KW - Time to diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85088933466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088933466&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2020.117054
DO - 10.1016/j.jns.2020.117054
M3 - Review article
C2 - 32763509
AN - SCOPUS:85088933466
SN - 0022-510X
VL - 417
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
M1 - 117054
ER -